The antitumor properties of recombinant human IL-7 (rhIL-7) on a human tumor was evaluated by engrafting a human colon carcinoma into immunodeficient mice and then treating the mice with rhIL-7 and adoptively transferred human peripheral blood T cells. It was found that rhIL-7 alone had no effect on the survival of the tumor-bearing recipients. However, the combination of rhIL-7 and human T cells significantly promoted the survival of the recipients compared with mice receiving either treatment by itself. When the surviving mice were analyzed 6 mo later for the degree of human cell engraftment, the recipients receiving both rhIL-7 and human T cells had greater numbers of human CD8 + T cells in the spleens. However, the human T cells recovered from the surviving mice showed low lytic activity against the tumor in vitro. Supernatants from human T cells cultured with the tumor and rhIL-7 in vitro were found to inhibit tumor growth and were demonstrated to contain high levels of IFN-y. Antibodies to IFN-y neutralized the growth inhibition of the tumor both in vitro and in vivo demonstrating that the in vivo mechanism underlying the antitumor effects of this regimen was partly dependent on the production of IFN--y by the T cells and not their cytolytic capability. Interestingly, systemic administration of rhIFN-'y to tumor-bearing mice yielded little antitumor effect suggesting that adoptive immunotherapy with rhIL-7 was superior possibly because of the continuous local release of the cytokines. Therefore, rhIL-7 may be of clinical use as an antineoplastic agent and the human/mouse model is a potentially important preclinical model for in vivo evaluation of the efficacy of this and other immunotherapies. (J. Clin. Invest. 1993. 92:1918 -1924 
Introduction IL-7 is a cytokine that was originally described as a factor produced by bone marrow stromal cells that exerted proliferative effects on B cell precursors in vitro ( 1, 2) . IL-7 also has been demonstrated to affect murine thymocyte proliferation in vitro (3) and to provide a costimulatory signal for resting T cells (4) . IL-7 has been shown to induce the proliferation of human T cells in vitro (5) and has been shown to augment lymphokine activated killer activity (6) , leading to the hypothesis that IL-7 may be of clinical use as an antineoplastic agent. In murine studies, it has been demonstrated that when IL-7 was transfected into tumor cells, the subsequent transfer of these cells into syngeneic recipients resulted in the increased rejection of the cells by T-cell-dependent responses of the host (7, 8) . Ad- ditionally, other studies performed in the mouse demonstrated that IL-7 induced cytotoxic T cells that could be adoptively transferred in vivo and protect mice against syngeneic tumors (9, 10) . However, the antitumor effects of recombinant human IL-7 (rhIL-7)1 against a human tumor have not been examined.
The ability to engraft human cells, both normal and neoplastic, into immunodeficient mice has allowed for the examination of various potential biological therapies on human tumors in an in vivo setting ( 1 1-13 ). In our studies, we chose to evaluate the efficacy of rhIL-7 against a human colon carcinoma in vivo. We report here that the administration ofrhIL-7 with adoptive immunotherapy (AIT) significantly prolonged the survival of human tumor-bearing mice. Furthermore, it was determined that the increase in survival was correlated with the production of IFN-'y by the human T cells in response to the tumor and rhIL-7. Thus, adoptive immunotherapy with rhIL-7 is worthy of clinical evaluation in cancer patients. In addition, these studies suggest that the human/mouse model may be useful in evaluating the in vivo efficacy of biological approaches to the treatment of human tumors.
Methods
Mice. C.B-17 scid/scid (SCID) mice were bred in our own colony at the NCI-FCRDC (Frederick, MD). Mice were used at 8-12 wk of age and were kept under specific pathogen-free conditions. SCID mice were housed in microisolator cages and all food, water, and bedding were autoclaved before use. SCID mice received trimethoprim/sulfamethoxazole (40 mg trimethoprim and 200 mg sulfamethoxazole/320 ml) in suspension in their drinking water.
Cytokines. rhIL-7 at 2-5 x 107 U/mg was kindly provided by Dr. Connie Faltynek (Sterling Winthrop Pharmaceuticals Research Division, Malvern, PA) rhIFN-'y at 2.5 X 107 U/mg was generously donated by Genentech Inc. (South San Francisco, CA).
Tumor cell line. The tumor cell line used for these studies was the HT29 human colon adenocarcinoma, which we have previously demonstrated grows in immunodeficient SCID mice ( 13) . The HT29 cells were maintained either by serial interperitoneal passage in athymic 1 . Abbreviations used in this paper: AIT, adoptive immunotherapy; huPBL, human PBL; LU, lytic units; NU, neutralizing units; rh, recombinant human; SCID, C.B-17 scid/scid (mice). 1918 mice or by growth in cell culture in DME supplemented with 10% FBS, L-glutamine (2 mM), sodium pyruvate (1 mM), nonessential amino acid solution ( 1%), and 50 IU/ml penicillin + 50 ,g streptomycin. For injection into mice, the cells were harvested and counted, and 1 X 106 viable cells were injected intraperitoneally. Tumor-bearing mice were then monitored for tumor development and progression. Moribund mice were euthanized. In the experiments where human T cells were also transferred, mice received an intraperitoneal injection of HT29 followed 2 h later with an intraperitoneal injection of 5 X I0' purified human T cells.
In vivo experiments. All mice received 20 Ml of anti-asialo GM1 (aASGM 1) (Wako Chemicals, Dallas, TX) intravenously to remove host natural killer cells ( 14) However, transfer of human T cells alone did prolong the survival ofthe tumor-bearing mice. The extent ofthe protection in the recipients receiving human T cells alone tended to vary with the huPBL donor. In some experiments, the recipients receiving human T cells alone did clear the tumor in a small percentage of mice, although the coadministration of T cells plus rhIL-7 was consistently superior in its protection, regardless of the donor when treatment was started the same day as (13, 14) , in most instances, CD8+ T cells predominantly engrafted in the mice (Fig. 2) . Additionally, these T cells also expressed HLA-DR, indicating that they were in an activated state fora prolonged period oftime in the SCID recipients. Interestingly, there was also no evidence of tumor in these long-term surviving mice, suggesting that rhIL-7 and AIT had indeed cleared some mice of a tumor burden of 106 cells. It was also demonstrated that administration of rhIL-7 could promote human lymphocyte engraftment in non-tumor-bearing SCID recipients (Table III) . Thus, rhIL-7 administration can improve long-term T cell engraftment in tumor-bearing SCID mice, which may contribute to the improved survival of tumor-bearing mice receiving this regimen. However, some mice receiving human T cells alone or human T cells with rhIL-7 were capable of clearing the tumor yet displayed little longterm T cell engraftment ( Fig. 2 and Table II) . Thus, other mechanisms may be responsible for the antitumor effects of rhIL-7 with AIT.
Cytotoxic capability ofhuman Tcells cocultured with tumor in vitro. We then wanted to determine the mechanism by which rhIL-7 and AIT protected the tumor-bearing mice. We had previously assessed the capacity of the recovered human cells from the surviving mice to lyse the tumor and demonstrated that the recovered human cells had no significant lytic activity towards the tumor in vitro (data not shown) (13) . Since it may be that the human T cells were initially cytolytic for the tumor, but after prolonged exposure in the murine host they lost their cytolytic ability, we then determined the effects of rhIL-7 on the generation of tumor-specific cytotoxic T lymphocytes after coculture in vitro. huPBL were cocultured with H LA-DR Figure 2 . Effects of rhIL-7 on long-term human T cell engraftment in tumor-bearing SCID mice. SCID recipients surviving the tumor for > 6 mo were killed and human T cell content was determined in the spleens ofthe mice by flow cytometric analysis. Representative ofthree experiments with two to three mice per group. tumor, with or without rhIL-7, for 4 d, and were then assayed for cytotoxic capability against the tumor. The results demonstrate that the human T cells only displayed significantly (P < 0.05) increased but modest levels ofcytotoxicity towards the HT29 tumor when 1,000 U/ml of rhIL-7 was included. However, when the huPBL were cultured with the tumor and rhIL-7 (> 100 U) significant (P < 0.05) increases in cytolytic activity were observed (Table IV) . Thus, the contribution of the cytotoxicity to the antitumor affects is not clear.
Induction ofcytokine production after coculture ofhuPBL with tumor and rhIL-7. We then assayed supernatants from the huPBL that were cocultured with tumor and rhIL-7 in vitro for any potential inhibitory effects on the HT29 tumor. We have previously demonstrated that the HT29 colon carcinoma is sensitive to rhIFN-,y and TNF-a in vitro ( 13 ) . When supernatants from human cells cocultured with rhIL-7 and tumor were placed with HT29 in vitro, the supernatants significantly inhibited the growth ofthe tumor (Table V) ( 13 ) . Neutralizing antibodies to TNF-a could only slightly reduce the inhibiting effects ofthe supernatants. To determine if rhIL-7 induces IFN-'y production by huPBL in vitro, the levels of IFN-,y were determined under the various culture conditions. It was found that rhIL-7 alone induced a dose-dependent production ofIFN-'y by huPBL after 4 d ofculture (Table IV) . Additionally, the coculture of the human T cells with the tumor resulted in high levels of IFN-y production. Yet, the coincubation of huPBL, rhIL-7 (> 100 U), and tumor resulted in significantly (P < 0.05) increased IFN-'y production compared to huPBL and HT29 alone. These in vitro results also suggest that the mechanism underlying the protective effects of rhIL-7 and AIT in tumor-bearing mice may be partially attributed to the production ofcytokines by the human T cells in response to rhIL-7. Thus, these cytokines had direct cytostatic or cytotoxic effects on the tumor in the absence of a cytotoxic T cell response. Although IFN-y appears to be critical to the growth inhibiting effects of rhIL-7 + T cells on HT29, it has been established that there is a strong synergy between IFN-'y and TNF-a on this cell line in vitro ( 13) . Thus, it is possible that both cytokines participate in the growth inhibition in vivo. Indeed combinations of IFN-y and TNF-a can result in substantial cytolysis of HT29 over a 4-5-d incubation period in vitro ( 13) . Therefore, it is possible that both IFN-'y and TNF-a production by the T cells in vivo plays an important role in therapeutic efficacy of this treatment regimen.
Effect of anti-IFN-,y antibodies in vivo on survival in tumor-bearing mice. The in vitro data shown in Tables IV and V implicated rhIFN-'y production as a possible mechanism for the antitumor effects ofrhIL-7 and AIT in tumor-bearing mice. Therefore, studies were initiated in which neutralizing antibodies to rhIFN-y were administered at the start ofrhIL-7 and AIT therapy. The results clearly demonstrate that the anti-IFN-'y antibodies significantly inhibited the antitumor effects ofrhIL- 7 and AIT in vivo (Fig. 3) . Thus, rhIL-7 promotes rhIFN-T production by human T cells in vivo in response to the tumor, and, in addition to the improved T cell engraftment stimulated by rhIL-7, the rhIL-7-induced IFN-'y can result in significant protection of SCID mice from a human tumor in vivo.
Comparison ofsystemic rhIFN-y administration and adoptive immunotherapy on survival in tumor-bearing mice. To compare the efficacy ofrhIL-7 and AIT versus systemic rhIFNy administration in vivo, tumor-bearing mice received either 2 X I05 U i.p. of rhIFN-'y daily for 10 d or rhIL-7 and AIT. The high dose regimen of rhIFN-y was tolerated by the SCID mice because of the species-specificity of rhIFN-y ( 15 ) (Fig. 4) . In marked contrast, mice given rhIL-7 and AIT demonstrated significant protection against the tumor. The results indicate that AIT is superior to systemic administration of cytokines, possibly because ofthe sustained local release ofcytokines by the human T cells in vivo.
Discussion
The data presented here demonstrate that rhIL-7 in combination with AIT consisting of human T cells will protect SCID mice from a human colon carcinoma. The mechanism of the Antitumor Effects ofRecombinant Human Interleukin-7 In Vivo 1923 protection is dependent on the production of IFN-y by the human T cells. This is the first instance in which rhIL-7 has been demonstrated to exert antitumor effects against a human tumor in vivo and suggests that rhIL-7 should be examined clinically as an antineoplastic agent. The data also demonstrate that although the production of IFN-y is essential for the antitumor effects of rhIL-7 and AIT, systemic administration of this cytokine, while capable of exerting significant antitumor effects in vitro, does not offer comparable protective effects in vivo. This implies that AIT offers distinct advantages as an antitumor therapy, possibly because of sustained and local release of IFN-,y, and possibly other cytokines from the adoptively transferred cells.
The human/mouse model, while offering many advantages for the preclinical evaluation of potential antineoplastic therapeutics, does have several significant limitations. It is still not clear ifprimary immune responses with human cells can be generated in SCID mice, although secondary responses have been shown ( 1 1, 16 ). Because ofthe selective pressures accompanying the placement of human T cells in a xenogeneic environment, the antitumor effects of rhIL-7 and AIT may be an indirect effect in response to exposure to the xenoantigens and not the tumor. Experiments are underway to determine if the human T cells do become specifically sensitized to the tumor in vivo. However, the human/mouse model does allow for the evaluation of anticancer therapies using human reagents directed against human tumors in an in vivo setting. Due to the fact that IFN-'y could inhibit tumor growth in vitro and yet systemic administration yielded little protective effect in vivo, this model may be very useful for the evaluation of various other cytokine therapies that have been proposed, since the complex in vivo milieu cannot be reproduced in vitro. Additionally, the model suggests that AIT may be of considerable use, when given in conjunction with rhIL-7 as an antineoplastic regimen. Studies are currently underway comparing the efficacy and toxicities of rhIL-7 and rhIL-2 in this model. It will also be important to test rhIL-7 and AIT against other tumors that are not sensitive to cytokines and to use tumors that are HLA-compatible with the human T cell donor to evaluate the ability ofparticular therapies to induce MHC-restricted killing.
It is also ofinterest that rhIL-7 induced significant cytokine (IFN-,y) production and not substantial cytolytic ability in the T cells cultured with the allogeneic tumor. Cytokine production by tumor infiltrating lymphocytes has recently been demonstrated to be a more relevant indicator of antitumor effects in vivo than cytotoxicity ( 17) . Our results also support that expression of in vitro cytotoxicity may not be a critical factor for a successful in vivo response.
In conclusion, rhIL-7 is shown to exhibit antitumor effects when given with AIT against a human tumor in vivo, suggesting that this cytokine may be ofbenefit as an immunomodulator in vivo and deserves further clinical evaluation. Furthermore, this work illustrates the advantages ofperforming in vivo evaluation of potential anticancer therapies using the human/ mouse model.
